← 治験一覧に戻る
mCRPC患者におけるアテゾリズマブとの併用によるカボザンチニブと2回目のNHTの比較試験
基本情報
- NCT ID
- NCT04446117
- ステータス
- 実施中（募集終了）
- 試験のフェーズ
- 第3相
- 試験タイプ
- 介入
- 目標被験者数
- 575
- 治験依頼者名
- Exelixis
概要
This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT for their prostate cancer disease.
対象疾患
Metastatic Prostate CancerProstate Adenocarcinoma
介入
Cabozantinib(DRUG)
Atezolizumab(DRUG)
Abiraterone Acetate(DRUG)
Enzalutamide(DRUG)
Prednisone(DRUG)